Teva Pharmaceutical Industries Limited's Latest EPS Top Last Year's by 39%
Teva Pharmaceutical Industries Limited (NAS: TEVA) reported earnings on Feb. 15. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Teva Pharmaceutical Industries Limited met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share contracted significantly.
Margins contracted across the board.
Revenue details
Teva Pharmaceutical Industries Limited reported revenue of $5.68 billion. The 23 analysts polled by S&P Capital IQ expected to see sales of $5.65 billion on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $4.42 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Non-GAAP EPS came in at $1.59. The 20 earnings estimates compiled by S&P Capital IQ predicted $1.59 per share on the same basis. GAAP EPS of $0.57 for Q4 were 33% lower than the prior-year quarter's $0.85 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 56.2%, 200 basis points worse than the prior-year quarter. Operating margin was 25.8%, 190 basis points worse than the prior-year quarter. Net margin was 8.9%, 860 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $5.56 billion. On the bottom line, the average EPS estimate is $1.45.
Next year's average estimate for revenue is $21.95 billion. The average EPS estimate is $5.59.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,470 members out of 2,533 rating the stock outperform, and 65 members rating it underperform. Among 633 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 627 give Teva Pharmaceutical Industries Limited a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries Limited is outperform, with an average price target of $53.50.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries Limited. Learn how to maximize your investment income and "Secure Your Future With 11 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
Add Teva Pharmaceutical Industries Limited to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
